Enfuvirtide vs PNC27
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Fuzeon, T-20
A peptide HIV fusion inhibitor that blocks viral entry into cells. First approved drug in the fusion inhibitor class.
Also: PNC-27, p53-HDM2 Disruptor Peptide
A chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. Selectively kills cancer cells by binding to HDM-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected.
Key Comparison Insights
- Enfuvirtide is FDA approved, while PNC27 remains in research stages.
- Both peptides belong to the Immune category, suggesting similar primary applications.
- Enfuvirtide has stronger research evidence (FDA Approved) compared to PNC27 (Animal Studies).
Detailed Comparison
| Attribute | Enfuvirtide | PNC27 |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Enfuvirtide is a 36-amino acid peptide that binds to HIV gp41, preventing the conformational change needed for virus-cell membrane fusion. This blocks HIV entry before the virus can infect the cell. | PNC27 contains two functional domains: residues 12-26 of the p53 HDM-2 binding domain on the N-terminus, and a membrane residency peptide (MRP/penetratin) on the C-terminus. Cancer cells uniquely express HDM-2 on their plasma membranes, while normal cells do not. PNC27 binds to this membrane-bound HDM-2, adopts an alpha-helical conformation similar to p53, and induces transmembrane pore formation. This causes extrusion of intracellular contents and rapid necrotic cell death. The peptide also enters cancer cells and disrupts mitochondrial membranes. Importantly, this mechanism is independent of intracellular p53 status - effective even in p53-null cancers. |
| Common Dosing | Limited community data available See research protocols | No human dose - research compound only Not applicable - no human use |
| Administration | Subcutaneous injection twice daily | IV injection in animal studies - not for human use |
| Typical Duration | Ongoing as part of HIV regimen | Research protocols only - no human use data |
| Best Time to Take | Morning or as directed | Per research protocol |
Possible Side Effects May vary by individual |
|
|
| Research Summary | TORO trials showed significant viral load reduction in treatment-experienced patients. Reserved for salvage therapy due to twice-daily injection requirement and injection site reactions. | Extensive in vitro research demonstrates PNC27 selectively kills multiple cancer cell types including breast (MCF-7), pancreatic (MIA-PaCa-2), cervical (HeLa, SW756), ovarian (OVCAR-3, OV-90), colon, lung, and leukemia (K562, U937, HL-60) cell lines. Effective concentration: 0.1-0.2 mg/mL kills most cancer cells. At 0.3 mg/mL, nearly 100% of K562 leukemia cells were killed. Studies confirm no toxicity to normal cells including fibroblasts and leukocytes. Mechanism involves membrane pore formation and necrosis (not apoptosis). Research published in PNAS and multiple peer-reviewed journals. |
Frequently Asked Questions: Enfuvirtide vs PNC27
What is the difference between Enfuvirtide and PNC27?
Enfuvirtide is a immune peptide that a peptide hiv fusion inhibitor that blocks viral entry into cells. first approved drug in the fusion inhibitor class. PNC27 is a immune peptide that a chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. selectively kills cancer cells by binding to hdm-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Enfuvirtide or PNC27?
Neither is universally "better" - the choice depends on your specific goals. Enfuvirtide is typically used for immune purposes, while PNC27 is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Enfuvirtide and PNC27 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Enfuvirtide and PNC27 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Enfuvirtide and PNC27 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.